Nur Baizura ZolkafliChin Sum CheongNur Adila Anuar0000-0001-6260-4553N. Veera Sekaran A/L V.NadarajanPing Chong BeeEdmund Fui Min ChinShasha KhairullahChee Chiat LiongMohd Yazid ZamriGin Gin Gan2025-10-302025-10-302025-01-0110.31436/imjm.v24i01.2560https://dspace-cris.utar.edu.my/handle/123456789/11637INTRODUCTION: The pathogenesis of classical myeloproliferative neoplasm (MPN) driven by JAK2, CALR and MPL gene mutations affects the clinical course and survival. This study aimed to determine the prevalence of driver mutations in MPN patients and their association with clinical presentations and outcomes. MATERIALS AND METHODS: We conducted a retrospective study involving patients with classical MPN diagnosed from 2002 to 2019. The patient's clinical and laboratory information, as well as outcomes, were collected and reviewed. RESULTS: 267 patients with classical MPN were recruited into the study. Majority of these patients were Chinese (46.5%), followed by Malay (40.1%) and Indian (12.7%). Most of the patients had essential l thrombocythaemia (ET) (57.3%), followed by polycythaemia vera (PV) (30.0%) and primary myelofibrosis (PMF) (12.7%). JAK2V617F mutation was detected in PV (87.5%), ET (68.0%), and PMF (67.6%) patients whereas CALR mutation was present in 15.0% of ET and 8.8% of PMF patients and MPL mutation was present in 0.7% and 5.9% of ET and PMF patients respectively. CALR-mutated ET patients were less likely to develop vascular events compared to JAK2V617F mutated patients (Odds ratio 0.301, 95% confidence interval 0.097–0.939, p=0.039). As for clinical outcomes, triple negative PMF patients had shorter median overall survival than those with JAK2V617F mutation (24.0 months vs. 161.0 months, p=0.017). CONCLUSION: Majority of classical MPN patients were Chinese with ET being the most common MPN subtype. The mutation profiles, clinical features, and survival outcomes were comparable to previous reports. Mutation studies are therefore important for prognostication and should be performed routinely. © (2025), (International Islamic University Malaysia). All rights reserved.enCALRclinical outcomesJAK2MPLmyeloproliferative neoplasmESSENTIAL THROMBOCYTHEMIACALRETICULIN MUTATIONSPRIMARY MYELOFIBROSISPOLYCYTHEMIA-VERACALR MUTATIONJAK2MPLSURVIVALSUBTYPESCLASSIFICATIONjournal-article